Pfizer bets on cancer drugs to recover from rapid decline of COVID business

Pfizer is pushing to be more involved in cancer drugs after a turbulent year marked by the rapid decline of its COVID business.During a four-hour investor event last week, Pfizer pushed its initative to “accelerate breakthroughs that help people with cancer globally live better and longer lives,” according to CNBC.The drugmaker has ramped up its efforts to “outdo cancer” since it acquired oncology biotech firm Seagen for $43 billion in December.The acquisition doubled Pfizer’s cancer drug pipeline to 60 dif ...